Parasitic Infectious Diseases

### **Chapter 5**

## Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination

*Aklilu Alemayehu*

### **Abstract**

Malaria recurrence not only increases its clinical episodes, but also sustains transmission. It significantly contributes to a high burden of malaria and impedes elimination. Malaria recurrence can be due to reinfection, relapse, or recrudescence. Based on the type of recurrence, parasites exhibit similar or dissimilar genotypes compared to the genotype involved in initial infection. This review aimed at showing a comprehensive overview of malaria recurrence. Molecular techniques, such as realtime polymerase chain reaction (PCR), nested PCR, multiplex PCR, and sequencing, help to characterize malaria recurrence. However, these tools are hardly accessible in malaria-endemic areas and are unable to detect liver hypnozoites. Moreover, PCR is unable to adequately differentiate between relapse and reinfection of *P. vivax*. Recurrent malaria, particularly relapse, accounts for major portion of malaria prevalence. Through renewed parasitemia, recurrence remained as a daunting public health problem. More works remain to overcome the challenges of recurrence in efforts to control and eliminate malaria. Limited understanding of malaria recurrence impedes the development of robust tools and strategies for effective mitigation. Continued biological and epidemiological studies help unravel the persistent complexities of malaria recurrence and develop ideal tool to fight malaria.

**Keywords:** *plasmodium*, recurrence, reinfection, recrudescence, relapse, malaria elimination

### **1. Introduction**

Recurrence of malaria is the return of malaria symptoms after varying lengths of symptom-free duration [1]. It often involves the reappearance of asexual stages of *Plasmodium* parasite in the peripheral circulation of a person, who was previously infected [1–3]. The reappearing parasite can be either similar or different to the genotype and/or species of the parasite responsible for primary infection [1, 2, 4]. Reemergence of asexual parasitemia can be due to persistence of the asexual parasite despite treatment; release from liver schizogony of reactivated hypnozoite; or from a novel infection [1].

Relapse and recrudescence are forms of recurrent malaria involving renewed parasitemia following hypnozoite reactivation and unsuccessful treatment, respectively. Reinfection involves the reappearance of malaria ensuing from the inoculation of sporozoites from an infected mosquito bite. Generally, depending on its source, malaria recurrence is classified into three types: relapse, recrudescence, and reinfection [1, 2]. The source of recurrence can be assessed by combining clinical findings with microscopy, genotyping, and measuring drug absorption [5].

### **2. Biology of malaria recurrence**

### **2.1 Reinfection**

Reinfection is renewed clinical illness or peripheral blood parasitemia due to a new infection with *plasmodium* parasite [6]. It appears after recovery from the primary infection, but usually involves different genotypes of the parasite [1, 5]. Malaria reinfection results from the injection of new sporozoites. It is critical to identify reinfection from other types of malaria recurrence for public health decision-making [5].

Markers currently employed to distinguish reinfection from other types of malaria recurrence include merozoite surface proteins (MSP1 and MSP2) and the gene of the glutamate rich protein (GLURP) [5, 7]. In reinfection, the reappearing parasite should not always exhibit a different genotype from the organism found at initial infection [1, 2]. However, all alleles of the posttreatment appearing parasite should be distinct from those identified in the pretreatment sample tested for one or more loci. This means it is possible to declare reinfection based on a single marker exhibiting disparity on all of its alleles between pretreatment and posttreatment samples [5, 7].

Reinfection is often associated with *P. falciparum* in endemic settings [8]. However, emerging reports show the possibility of reinfection with other species of *Plasmodium* [8, 9]. Likewise, Lau *et al.*, reported reinfection with a nonhomologous strain of *Plasmodium knowlesi* from Malaysia [10]. In the case of *Plasmodium vivax*, reinfection could be disregarded if the patient relocates to settings with no malaria transmission [9]. Particular attention is vital to characterize involved species and the corresponding management [8]. Besides, reinfection further exacerbates transmission dynamics with its potential to activate hypnozoite; introduce new strains and/or species to result in heterologous relapse, and provide a chance for immune evasion. Generally, malaria recurrence increases efficiency, chance, and longevity of malaria transmission in so doing it threatens the productivity of interventions [11].

Reinfection can play a remarkable role in sustaining both the clinical and epidemiological impact of malaria. Reinfection with *P. vivax* entails relapse from itself and/or from the latent infection [9]. Similarly, reinfection with *P. falciparum* triggers relapse, thereby complicating the disease and the subsequent transmission potential [12]. In areas with high transmission of malaria, slowly eliminated antimalarial drugs are used to clear parasitemia and reduce the risk of subsequent reinfection [13]. Appropriate case management can potentially reduce parasite transmission [14]. Frequent reinfections can arise from the poor yield of interventions. Therefore, reinfection is a good marker for the effectiveness of preventive activities, such as vector control [9, 14, 15].

*Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

### **2.2 Relapse**

Malaria relapse is hypnozoite-mediated reemergence of malaria symptoms following a successful clearance of bloodstream parasitemia. It is characterized by the recurrence of asexual parasitemia ascending from hypnozoite stages of past infection [1–3, 16]. The dormant hypnozoites persist in the liver and mature to form hepatic schizonts. These hepatic schizonts rupture and release merozoites into the peripheral circulation with an interval commonly ranging from 3 weeks to 1 year [1, 2, 17, 18]. Relapse is common in *P. vivax* and *Plasmodium ovale* infections [2, 16, 19].

Liver hypnozoites can be formed either at initial infection from the newly inoculated *Plasmodium* or during the existing infection from the erythrocytic *Plasmodium*. In areas where *P. falciparum* and *P. vivax* are co-endemic, the newly inoculated sporozoites of *P. vivax* sometimes directly go to the dormant stage in the liver as a strategy to avoid the potential damage that can result from the competition with *P. falciparum* in the bloodstream [20]. Reactivation of dormant hypnozoite occurs in response to the creation of favorable conditions due to various factors, such as a change in host immunity or inoculation of new *Plasmodium* [4, 12].

For a long time, relapse is considered as the hypnozoite-mediated reappearance of clinical malaria [16]. However, recent developments suggest the possibility of relapse from the reappearance of erythrocytic plasmodial stages from bone marrow and spleen. According to studies on nonhuman primates and humans, bone marrow is a key tissue reservoir of *P. vivax* schizonts [21–23]. Apart from a hypnozoite origin, another noncirculating source bringing about homologous parasitemia results in relapse-like *P. vivax* recurrences, which would better be regarded as recrudescence than relapse [6]. This concept raises the question of differentiating the parasite population arising from hypnozoite and non-hypnozoite-driven recurrences [22].

Recurrence from noncirculating and non-hypnozoite sources, adds to the longstanding complexities of malaria biology and epidemiology, particularly vivax malaria [6, 16, 19, 21, 23]. Peripheral parasitemia is a poor indicator of parasite biomass in a patient [6, 22, 23]. Therefore, assessing the involvement of the hematologic niche in malaria recurrence is gaining attention from the scientific community to improve the understanding of the pathogenesis of recurrence and reinforce the fight against malaria [3, 21–23].

Recurrences due to *P. vivax* can be homologous or heterologous, either of which can be reinfection, recrudescence, or relapse [4, 6, 22, 24]. Besides, different populations of hypnozoites derived from repeated inoculations can be found in the peripheral blood of a person [17]. This introduces difficulty in discerning the type of recurrence in *P. vivax* [4]. However, it is possible to consider most homologous recurrences as relapse provided recrudescence can be excluded in areas with high genetic diversity of *P. vivax* [4, 20]. Yet, relapse rates might be underrated since they can sometimes contribute to heterozygous recurrence due to polyclonal inoculum by a mosquito [4, 6, 17, 22].

The relapse of *P. vivax* usually ranges from weeks to a year [17, 20]. However, according to controlled human malaria infection, the frequency and number of relapses differ with host immunity and geographical location. In tropical areas, the risk of relapse is high with short intervals (less than a month); whereas temperate and subtropical areas are characterized by a lower risk of relapse recurring after a long latency (8–12 months) [17, 25]. Consistent with this, patients in regions of short relapse periodicity had a greater rate of *P. vivax* parasitemia than those in regions of long relapse periodicity (HR = 8.61 95% CI: 2.34–31.65; P = 0.001) [17]. In addition to places, the severity of relapse illness shortens the periodicity by activating more hypnozoites in the liver [20]. Conceivably, a modeling result shows a shorter latent period of hypnozoites increases *P. vivax* recurrence further reinforcing the problem (**Figure 1**) [26, 27].

### **2.3 Recrudescence**

Recrudescence of malaria is the return of malaria symptoms after symptom-free periods. It is caused by parasites surviving in peripheral circulation despite treatment [1]. Recrudescence is characterized by the reappearance of genetically similar asexual stage parasites to the initial infection, usually due to incomplete therapy. In recrudescence, at least one allele at each locus is common to both paired samples collected at primary infection and recurrence [5, 16]. Recrudescence often results from incomplete clearance of asexual parasites by antimalarial drugs. It is common in infections with *P. malariae* and *P. falciparum* [1, 2].

Recrudescence associated with failure to prevent or cure malaria does not necessarily mean drug resistance. It can also be a temporary drug-associated quiescence, whereby ring stages of *P. falciparum* parasite in the RBCs become temporarily dormant ensuing exposure to artemisinin derivatives, such as dihydroartemisinin [28]. Based on this phenomenon, it is conceivable that early homologous recurrence of *P. vivax* might be misclassified as relapses while being recrudescence resulting from temporary drug-induced dormancy. In the absence of PQ therapy, the use of whole-genome analysis might help resolve such uncertainty [24]. Recrudescence should be properly characterized as it carries a considerable public health challenge (**Table 1**) [29].

### **Figure 1.**

*Pathogenesis of infection, and recurrence with P. vivax. Hypnozoite and schizont infection of liver occur following inoculation of sporozoites. However, after the inoculation, the parasite may develop and multiply to cause blood infection (upper row) or may enter into long-term latency (lower row). Furthermore, a portion of the hypnozoites remains in the liver to continue to relapse periodically. Suggested intervention strategies at specific weak spots are indicated (green shades inside Brocken-lined boxes). MDA: Mass drug administration.*

*Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*


**Table 1.**

*Comparison of different types of recurrence in malaria.*

### **3. Management of malaria recurrence**

### **3.1 Diagnosis of malaria recurrence**

Proper laboratory diagnosis forms the foundation for achieving malaria control and elimination. Accurate, reliable, and timely results are essential to managing initial and recurrent episodes of malaria [30, 31]. The effectiveness of malaria intervention is a function of the right diagnosis at the right time and the right treatment. Treatment without laboratory confirmation may result in overtreatment with antimalarials that may facilitate the development of drug resistance and waste resources [8, 32]. Malaria case management solely based on a clinical diagnosis not only reduces the effectiveness of treatment outcomes but also worsens the clinical and epidemiological burden of malaria by paving the way for recurrence and transmission [8].

Malaria microscopy, so far, has been the mainstay to detect and identify *Plasmodium* parasites. However, this method suffers from deficiency to detect very low density of parasites and difficulty to identify recurrences [33]. Molecular diagnosis provides optimum sensitivity and specificity to characterize malaria recurrence. Distinguishing recrudescence from reinfection is important to monitor the effectiveness of the therapeutic intervention. Molecular tests, such as PCR, employ genotyping target genes of the *Plasmodium* for diagnosis of malaria recurrence [14, 32].

Genotyping *Plasmodium* parasites is fundamental to comprehending parasite biology; clinical management and innovation of tools to mitigate disease. *Plasmodium* parasites vary by pathogenesis; susceptibility to drugs; recurrence pattern; and transmissibility by mosquito species. Genotyping these parasites help to describe

the current population, understand the relationship among various populations, and characterize clinical and epidemiological features [34]. The polymerase chain reaction is a powerful tool to detect and identify *Plasmodium* parasites with high sensitivity and high specificity, respectively [35]. Generally, genotyping stands at the forefront of malaria elimination [5, 33, 35].

Recent advances in molecular techniques have improved the detection and identification of malaria parasites [14, 34]. Unlike microscopy and rapid diagnostic tests (RDTs), molecular techniques involving PCR help to identify and characterize recurrences [30]. They are essential partners in the control and elimination of malaria, as they both help detect and prevent recurrence through increased sensitivity and specificity [34]. They help detection of sub-microscopic, asymptomatic, mixed, and multiclonal infections in addition to suggesting drug resistance possibility [36]. Hence, molecular techniques substantially improved case management by revealing these contributors to recurrence in various ways [30, 32].

Generally, although molecular tests ominously revolutionized the interventions against malaria, some works remain to further improve their yield in the fight against malaria. There is no reliable laboratory test to diagnose liver-stage hypnozoites of *P. vivax* [37]. Besides, in the case of *P. vivax*, it is difficult to differentiate between relapse, recrudescence, and reinfection, as they might involve parasites with similar or different genotypes to the parasite found in an initial infection. Due to their high cost and technical complexity, molecular tests are not readily available in developing countries with a high burden of malaria [5, 38].

### *3.1.1 Nested polymerase chain reaction*

Nested PCR is a type of PCR that involves two sets of primers used in two sequential runs of PCR. It is a technique, whereby the first PCR generates a mix of all *Plasmodium* species DNA products, which can be used in the second PCR run with primers internal (nested) to the first pair of primers. The first amplification, nest 1, allows detection of the *Plasmodium* genus-specific genes. Products of samples tested positive will then be subjected to a further four nested reactions (for four species) to determine the species compositions [35]. The purpose of the second run is to amplify a secondary target (species-specific sequence) within the first run product. It is an ideal technique for increasing the sensitivity and specificity of PCR [5, 33, 35].

The nPCR assay genotypes malaria parasites by targeting marker genes for 18S rRNA, merozoite surface proteins (MSP1 and MSP2), and gene of the glutamate rich protein (GLURP). Detection of amplicons from nPCR is usually done by agarose gel electrophoresis. Besides, these markers help to discriminate recrudescence from reinfection [35]. These markers possess varying power to discriminate between *Plasmodium* species. Accordingly, while MSP2 and GLURP have similar power, MSP1 has lower discriminatory power than these two markers. Despite the vulnerability of GLURP to "artifact bands," and the varying performance of different markers across different geographical places, the general discriminatory power is constant [5].

Despite its remarkable benefits, nPCR is susceptible to contamination due to its extreme sensitivity and involvement in sample manipulation. Contamination originates from human errors due to the transfer of parasite material between samples or between samples and PCR reagents. The other type of contamination, which is more serious, occurs when PCR product from either of the two runs is exposed to samples, reagents, or equipment. Furthermore, the use of two separate reactions makes nPCR costly (**Figure 2**) [35].

*Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

#### **Figure 2.**

*Schematic diagram of nested PCR. The nPCR involves two-stage amplification of the target DNA of malaria parasites by using two sets of primers that target species- and genus-level markers of the plasmodium. The external primer targets genus-level-marker: 18S rRNA, whereas the internal primer targets species-level-marker: MSP1, MSP2, and GLURP. The first run may produce unwanted products. A portion of amplicons from the first run is used as a template in each of four separate PCR reactions to produce uncontaminated final products.*

### *3.1.2 Real-time polymerase chain reaction*

Real-time polymerase chain reaction (PCR) is usually referred to as quantitative PCR (qPCR) since it involves detection, identification, and quantification of target DNA data as it occurs. It is characterized by continuous monitoring of amplicons production from the parasite DNA by using fluorescent-labeled reporters, including DNA intercalating dyes, such as SYBR green, and sequence-specific probes [39]. Realtime PCR targets polymorphic regions of MSP1, MSP2, and GLURP and are present simultaneously or singly on the *Plasmodium* parasite [40].

Real-time PCR can play an important role in characterizing malaria recurrence through simultaneous detection and quantification of the *Plasmodium* parasite. It allows multiplexing that will provide a critical framework for the identification of parasites involved in reinfection, recrudescence, and relapse. Besides, as well as can help detect genes responsible for resistance to antimalarial drugs, thereby helping the chance of malaria recurrence and transmission [41–43]. Moreover, due to its good sensitivity and specificity, real-time qPCR can be useful in both epidemiological and clinical studies as well as early detection of cases that might entail recurrence (**Figure 3**) [44].

### **Figure 3.**

*Graphical presentation of real-time PCR principle (TaqMan system). Real-time PCR involves a probe that is labeled at the five prime ends with a fluorescent reporter dye (F) and at the three prime ends with a quencher dye (Q ). In intact probes, the fluorescence of the reporter is quenched by the close presence of a quencher. Then, probes and the complementary DNA strand are hybridized and reporter fluorescence is still quenched. During extension step of the PCR, the probe is degraded by the Taq polymerase and the fluorescent reporter is released resulting in florescence emission, which is essential information to detect and quantify the target sequence. PCR: Polymerase chain reaction, Taq pol: Taq polymerase, Q: Quencher, and F: Fluorophore [42].*

### *3.1.3 Multiplex polymerase chain reaction*

Multiplex PCR is a molecular technique characterized by simultaneous detection of several targets within a single reaction by using diverse pairs of primers specifically designed for each target [41]. In context of malaria, specie-specific primers labeled with different fluorescent dyes targeting MSP and GLURP markers are contained in the master-mix used to detect five species of *Plasmodium* by a single run [40]. The recently developed multiplex malaria sample ready PCR showed a hopeful result in Sierra Leone by demonstrating twice and four times higher sensitivity compared to malaria RDT and microscopy, respectively [45].

Multiplex PCR provides more information with fewer samples in a reasonably short time. It allows the detection of multiple species of *Plasmodium* from a single sample with a single run, thereby contributing to characterizing types of recurrence for proper case management and research purpose. In general, multiplexing is an excellent cost-saving strategy, with a particular implication in resource-limited settings [40]. However, multiplex PCR suffers from process complexity, poor universality, and variability in efficiency for different templates. Furthermore, multiplex PCR showed relatively lower sensitivity than nPCR for *Plasmodium* species due to the competition between different amplicons for limited supplies found in the reaction well (**Figure 4**) [40, 47].

*Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

### **Figure 4.**

*Diagram showing the multiplex PCR approach [46]. Multiplex PCR is a type of PCR in which multiple target DNA are simultaneously amplified in a single reaction tube. It involves the use of specific primers that can specifically combine with their corresponding DNA target contained in a master-mix, and hence allow amplification of more than one DNA fragment from a single and/or many samples.*

### *3.1.4 Sequencing*

Sequencing is the process of determining the order of nucleotides in a piece of DNA. It can be done in a small targeted genomic region or entire genome of an organism, including *Plasmodium* parasite [48]. A single-cell level sequencing *Plasmodium* parasites to explore parasite relatedness in Malawi proved the possibility of emergence of a new strain within an individual from super-infection with *P. falciparum* due to repeated reinfection. This study also reported unexpectedly frequent co-transmission of related parasites in intense transmission settings in the country, thereby intensifying possibility of recurrence and transmission [49].

Whole genome sequencing of *P. vivax* isolates from Ethiopia revealed frequent sequence and structural polymorphisms in erythrocyte binding genes that code for Duffy antigen/chemokine receptors [50]. The currently emerging data suggest that MSP involved in RBC adhesion is rapidly evolving [50, 51]. This signals for expanding pattern of *P. vivax* in areas previously considered not affecting Duffy-negative individuals [50]. Moreover, sequencing data can help characterize recurrence, particularly strains involved in relapse, which is inevitable since the parasite continues to infect both Duffy-negative and positive people [50, 51].

Amplicon sequencing involves sequencing a particular DNA segment of a parasite we are interested in. It helps to identify a single nucleotide polymorphism in the *Plasmodium* parasite [52]. Amplicon sequencing helps to characterize the genetic diversity of *Plasmodium* parasites by showing the number of alleles in a population in time and space. It serves as an ideal tool for characterizing the spatiotemporal flow of *Plasmodium* infection and geographical tracking of transmission patterns, including new and recurrence [52]. It is also an important tool to assess drug resistance genes, particularly by detecting the kelch 13 (K13) propeller gene of *P. falciparum,* thereby

allowing recrudescence characterization [53, 54]. Furthermore, next-generation sequencing enables determining the transmission dynamics of *Plasmodium* species [55]. Nevertheless, these parasite sequencing methods are costly and are not sufficiently standardized for extensive use in field and clinical settings, particularly in malaria-endemic settings (**Figure 5**) [52, 55].

### **3.2 Treatment and/or prevention of malaria recurrence**

Primaquine is the only drug widely applied to prevent relapse by clearing liver hypnozoites [27]. Recently shreds of evidence are emerging on the possibility of preventing malaria relapse with a single dose tafenoquine (TQ ) treatment [56]. Universal radical cure with ACT and PQ/TQ is hoped to reduce parasitemia by leveraging the high risk of *P. vivax* parasitemia following *P. falciparum* infection in co-endemic settings [57]. This strategy produced a remarkable reward within one year by bringing about a 90% reduction in parasitemia of *P. vivax* among a cohort of children in Papua New Guinea [17, 58].

Preventing recurrent parasitemia reduces morbidity and mortality directly associated with malaria and indirectly with other secondary diseases [59]. Besides, a comprehensive treatment policy for malaria provides considerable benefits at an individual, public health, and operational level in settings, where *P. falciparum* and *P. vivax* are co-endemic. For prevention of recurrence, particularly relapse of *P. vivax*, establishing strong adherence to a full dose of PQ as a radical cure can strengthen control and elimination efforts [37]. Individuals carrying a high load of hypnozoites are more likely to relapse and therefore be targeted for treatment with PQ [60].

Improved case management is pivotal to prevention and control of malaria recurrence, particularly recrudescence. Use of highly sensitive molecular tools, such as PCR, help to detect submicroscopic parasitemia, and hence treatment [8, 31]. On the other hand, strengthening vector control strategies is important to prevent reinfection by protecting from infectious mosquito bites [8].

Hypnozoiticidal therapy against latency is used to prevent relapses from *P. vivax* and *P. ovale* [7]. The G-6-PD status of patients should guide the administration of PQ to prevent relapse. To prevent relapse, treat *P. vivax* or *P. ovale* malaria in children and adults with a 14-day course (0.25–0.5 mg/kg/BW/day) of PQ in all transmission settings. Nevertheless, this recommendation excludes pregnant women, infants aged below 6 months, women breastfeeding infants aged below 6 months, women breastfeeding older infants with unknown G-6-PD status, and people with G-6-PD deficiency. In people with G-6-PD deficiency, with close medical supervision for the risk of PQ-provoked hemolysis, consider preventing relapse by giving PQ base at 0.75 mg/kg/BW/week for 8 weeks. If the G-6-PD status is unknown and G-6-PD testing is not available, a decision to prescribe PQ must be based on risks and benefits [37, 61].

### **Figure 5.**

*Overview of DNA sequencing. DNA sequencing involves preparation of target DNA (sample collection and nucleic acid extraction); library preparation (adaptor ligation, size selection, and amplification); sequencing and data analysis (base calling, alignment, and annotation).*

### *Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

Tafenoquine is a single-dose (300 mg) drug approved only for use in combination with chloroquine (CQ ) for adult patients who are nonpregnant and G-6-PD-normal. Before administering TQ, make sure the patient has normal G-6-PD activity (>70% [7, 61]. In pregnant or breastfeeding women, consider weekly chemoprophylaxis with CQ until delivery and breastfeeding is completed. Then, based on their G-6-PD status, treat with PQ to avoid future relapse [61].

### **4. Epidemiology of malaria recurrence**

### **4.1 Prevalence of malaria recurrence**

### *4.1.1 World*

Malaria recurrence is a daunting public health problem worldwide. It increases the incidence and prevalence of malaria [9, 26, 60]. In many regions, a large portion of *P. vivax* prevalence is attributed to relapse [9, 16, 62]. A long-term study conducted on Thai-Myanmar border revealed a higher rate of *P. vivax* than *P. falciparum* recurrence, with a cumulative proportion of 31.5% (95% CI: 30.1–33.0%) and 21.5% (95% CI: 20.3–22.8%) recurrence by day 63, respectively [63].

In the recent meta-analysis by Hossain *et al.*, recurrent parasitemia of *Plasmodium* species between day 7 and 42 was documented among 13.2% of patients worldwide, mainly of *P. vivax* recurrence. In the same report, the cumulative risks of recurrent parasitemia of any *Plasmodium* species by day 28, 42, and 63 were 8.1% (95% CI: 7.7–8.6), 16.8% (95% CI: 16.2–17.5), and 30.5% (95% CI: 29.4–31.6), respectively [12]. Additionally, a comprehensive review involving many studies across Asia, the Americas, and Africa showed a recurrence of *P. vivax* in 30% of people within 2 months after ACT [64]. In India, a country with a high burden of *P. vivax* region, 17.1% average relapse rates of *P. vivax* with quickly recurring type have been recorded from 2001 to 2003 [65]. Likewise, in Brazil, 23% of reported cases of *P. vivax* malaria relapse [66].

Relapse persisted as the contributor to the overall prevalence of recurrent malaria worldwide. A genotyping and whole-genome sequencing conducted in Cambodia for assessing the efficacy of CQ against *P. vivax* indicated that two-thirds of the recurrent *P. vivax* parasites resulted from heterologous relapses [67]. The incidence density of *P. vivax* recurrence was 45.1/100 patient-years, mostly occurring between the 4th and 13th week after initiating treatment [66]. The cumulative incidence of the first recurrence of *P. vivax* infection among patients receiving CQ and PQ in Turbo Municipality, Colombia, was 24.1% (95% CI: 14.6–33.7%). The majority (65.5%) of these recurrences were classified as relapse and occurred within 51 to 110 days of follow-up. High genetic diversity (12.5%) of *P. vivax* strains was recorded in the area. In general, relapse from *P. vivax* infection is responsible for the majority of recurrent malaria [68].

Recrudescence, with its potential to reveal treatment failure, carries an essential implication for the effectiveness of malaria treatment [5]. Recrudescence of *P. falciparum* 13 years after exposure was reported from Liberia. This woman is 49 years old with no history of traveling outside Canada, and never received a blood transfusion [69]. Recrudescence of *P. falciparum* after 4 years in a Ghanian pregnant woman living in Italy raised a speculation on the role of pregnancy triggering too late recrudescence by impairing preexisting immunity. Additionally, after relocating from a malaria-endemic area to a nonendemic area, patients may lose their immunity and develop recrudescence of the chronic *P. falciparum* infection [70].

### *4.1.2 Sub-Saharan Africa*

Given the quality of interventions, co-endemicity of parasites, and climatic conditions, recurrence remains a formidable problem in sub-Saharan Africa [71]. Recrudescence of *P. falciparum* 13 years after exposure of a woman was reported in Liberia. This woman was 49 years old with no history of traveling outside Canada and never received a blood transfusion [69]. In Malawi, nearly 30% of children treated for malaria are reinfected within 42 days of treatment [72]. Greater immunity to *P. vivax* was conferred by reinfection with homologous parasite strain than with heterologous parasite strain. This was indicated by a reduction in the geometric mean of parasite count and in fever episodes from primary infection to reinfection [73]. These findings reflect the remaining problem in sub-Saharan Africa despite progress in the twentyfirst century [74].

### *4.1.3 Ethiopia*

Ethiopia as a sub-Saharan African country with a 75% malarious landmass, where *P. falciparum* and *P. vivax* are co-endemic, suffers from multidimensional burden of malaria and its recurrence. The risk of malaria recurrence in Ethiopia by day 28 and day 42 was 2.8% (95% CI: 0.9–8.4%) and 6.7% (95% CI: 3.2–13.5%), respectively [75]. The risk of *P. vivax* infection following treatment with rapidly eliminated treatments needs attention. After radical cure of primary *P. vivax* infection with PQ and CQ, 0.4 *P. vivax* infections/person/year was reported from Ethiopia by Abreha *et al*. [76]. Assuming these all as reinfections and the potential of slowly eliminated ACTs, the expected risk of *P. vivax* recurrence by day 63, 3.8% incidence is estimated in Ethiopia [12].

Malaria recurrence is among important public health problems in Ethiopia. An open-label trial aimed to assess the effectiveness of artemether lumefantrine (AL) in Jimma Zone by Eshetu *et al.,* detected a 3.8% and 5.1% reinfection and recrudescence of *P. falciparum* by day 42, respectively. The same study identified a higher (9.4%) rate of *P. falciparum* recrudescence among children aged below 6 years in the Jimma zone. The lower capacity of children to sufficiently metabolize the drug has been suggested for the therapeutic yield [77]. Similarly, recurrent parasitemia rates of 19% and 7.5% after 28 days following treatment with AL and CQ, respectively, were observed in Ethiopia. This was considered as the incidence rate of treatment failure using *in vivo* parameters [78]. Furthermore, Teklehaimanot and his colleagues reported recurrent episodes of vivax malaria despite the use of an optimum dose of PQ and relocation of patients to a non-malarious area, from Gambella to Addis Ababa. This report alarms failure of PQ to prevent relapse in Ethiopia, where *P. vivax* is responsible for 40% of malaria prevalence (**Figure 6**) [79].

### **4.2 Factors affecting malaria recurrence**

The recurrence of malaria depends upon various factors. These factors can be associated with the human host (gender, gene, and others), the *Plasmodium* parasite (specie, mono or mixed infection, and density), and intervention deployed (type of antimalarial drug) [12, 17, 80–82].

*Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

### **Figure 6.**

*Overview of malaria recurrence and its public health importance. Malaria recurrence can assume various forms depending upon the species of the plasmodium and other factors. (A) Primary infection due to inoculation of sporozoites by infected mosquito. (B) Sub-microscopic parasitemia is often missed by conventional diagnostic tools. (C) Infection with malaria parasites can be primary or recurrence. (D) Factors arising from the human host, the parasite, or intervention can determine the type of malaria recurrence. (E) Hypnozoites from the liver can give rise to recurrence or vice versa. (F) the prevalence of malaria recurrence depends on places, human hosts, type of drugs used, and season. (G) Recurrence is characterized by renewed parasitemia in peripheral circulation due to relapse, reinfection, or recrudescence. (H) Public health implication of malaria recurrence. Colored small circles: Green = new parasite injected as sporozoite, pale blue = hypnozoites from newly injected parasites, purple = existing parasites as sub-microscopic in the circulation, and red = long existing hypnozoite.*

### *4.2.1 Human host factors*

### *4.2.1.1 Genetic factors*

The pattern of malaria recurrence, especially relapse, depends on host factors; including the cytochrome enzyme responsible for metabolizing anti-relapse drug. The prominent anti-relapse drug, PQ, is converted into its active metabolites in the liver by monoamine oxide and CYP2D6 (isotype of cytochrome P450 [CYP450]) enzymes [81]. CYP2D6 is naturally polymorphic, and its variant is widespread; up to 25% of the world's population. This variant is associated with a substantial decline in efficacy of PQ putting people with this variant gene at higher risk of relapse [82, 83]. The host immune efficiency to clear parasitemia during the initial infection is important for the possibility of future recurrence [17]. The risk of *P. vivax* recurrence among patients who failed to clear their initial parasitemia within 2 days (AHR = 1.8 95% CI: 1.4–2.3; P < 0.001) [12]. People with a deficiency of the G-6-PD enzyme, owing to their ineligibility to PQ and TQ, carry a higher risk of vivax malaria recurrence [9, 61]. Pregnant and those breastfeeding children below 6 months, G-6-PD-deficient individuals, and children below 6 months do not receive PQ, and hence are at risk of recurrence [84, 85]. Also, according to a mathematical modeling study in Brazil, once infected with *P. vivax*, 23% of pregnant women are at risk of one or more episodes of vivax recurrence within 3 months [86]. Another modeling result shows the rise in *P. vivax* recurrence with an increase in the proportion of people with G-6-PD deficiency in the population [26].

### *4.2.1.2 Age*

Being at a younger age raised the risk of *P. vivax* infection recurrence in the Thai-Myanmar border (P = 0.001) [63]. Patients with younger age (AHR = 3.04 95% CI: 2.39–3.87, P < 0.001) carry a greater risk of developing recurrent *P. vivax* parasitemia than adults [12]. Likewise, Antonio *et al*. 2021, recently reported a higher frequency of malaria recurrences among children under 4 years [87]. Slow clearance of parasites due to dose variation by age and weight; and subtherapeutic dose due to manipulation to overcome the bitter taste of drugs, particularly CQ, are some of the factors that are suggested to escalate the frequency of recurrence among children [87–89].

### *4.2.1.3 Gender*

Male gender increased the risk of recurrence during the year in Brazil and Thailand [62, 63, 66]. Male patients (AHR = 1.26 95% CI: 1.08–1.46; P = 0.003) carry a greater risk of developing recurrent *P. vivax* [12]. This might be due to the behavior of the male that exposes him to a new infection with *P. falciparum*, which in turn triggers relapse. Additionally, more proportion of males is not eligible for PQ than females, which might raise the risk [12, 80, 90].

### *4.2.2 Parasite factor*

Parasite-related factors, such as species, strain, density, and stage, play a fundamental role in the pattern of malaria recurrence [9].

### *4.2.2.1 Species*

Species of the offending parasite are the leading factors driving malaria recurrence. *P. vivax* is responsible for the majority of recurrent malaria [9, 87]. A long-term study conducted on Thai-Myanmar border, revealed a higher frequency of *P. vivax* than *P. falciparum* recurrence, with a cumulative proportion of 31.5% (95% CI: 30.1–33.0%) and 21.5% (95% CI: 20.3–22.8%) recurrence by day 63, respectively [63]. Similarly, other supportive findings show the contribution of *P. vivax* for at least 70% of malaria recurrences [12, 62].

### *4.2.2.2 Density*

The density of parasites, mainly the load of asexual parasites in the peripheral circulation enhances recurrence, particularly recrudescence, by giving resilience to the dose of treatment. Higher parasitemia and a shorter time since the onset of symptoms in the initial infection increased the risk of relapse during the year in Brazil and the Thai-Myanmar border [63, 66]. A similar effect of hyperparasitemia on severe recrudescence was observed in France, where a polyclonal infection and high load of parasites increased the risk in a participant, who returned from Chad [91]. On the other hand, patients with high parasite count (AHR = 1.59 95% CI: 1.22–2.08; P = 0.001), carry a greater risk of developing recurrent *P. vivax* [12]. Furthermore, according to a modeling study, individuals with more hypnozoites are predicted to experience more relapses [60].

### *4.2.2.3 Mixed-infection*

In areas, where *P. falciparum* and *P. vivax* malaria are co-endemic, patients treated for *P. falciparum* infection have a high risk of subsequent *P. vivax* malaria. According to Commons *et al.*, the risk of *P. vivax* parasitemia after *P. falciparum* at day 63 was 24% [12]. A series of RCTs in Thai-Myanmar revealed that a mixed infection and

*Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

*P. falciparum* gametocytemia at enrollment raised the risk of *P. vivax* recurrence (P = 0.001) [63]. Similar other studies indicated the increased risk of relapse of *P. vivax* after infection with *P. falciparum* [80]. This suggests the potential role of *P. falciparum* infection to trigger the dormant *P. vivax* [12, 80]. Due to the suppression by *P. falciparum*, *P. vivax* disappears from the blood without reaching a density that can elicit a host immune response. Taking this defeat as a chance or tactic, *P. vivax* reemerges after weeks or months by generating transmissible densities of gametocytes. Besides, in low transmission settings, when immunity to *P. falciparum* is weak, falciparum malaria in adults may trigger dormant hypnozoites of *P. vivax* due to its capacity to trigger fever [20].

The growing pieces of evidence from all over the world about the correlation between the risks of *P. vivax* after *P. falciparum* treatment raise curiosity that the immune response of the host to acute malaria might trigger the revival of *P. vivax* hypnozoites. Besides, although the exact mechanism remains unclear, fever and hemolysis in *P. falciparum* infection are the suggested triggers for relapse [12, 80]. According to the report of the study in Thailand by Douglas *et al.*, 51% of patients diagnosed with acute infection of *P. falciparum* and treated with a rapidly eliminated drug suffered a relapse of *P. vivax* after just 2 months [63]. Furthermore, a meta-analysis of clinical trials on *P. falciparum* by Commons *et al.* demonstrated that within 63 days, 24% of *P. falciparum* patients suffered from a *P. vivax* recurrence. This review reported that nearly 70% of malaria recurrences are due to *P. vivax* [12]. Taken together, these shreds of evidence not only show the sizeable input of relapse to the general epidemiology of malaria but also demonstrate how relapse wisely uses the inoculated sporozoites to optimize the survival of these species [11, 20].

### *4.2.3 Intervention-related and other factors*

### *4.2.3.1 Drug*

Drugs are profound determinants of malaria recurrence [63]. According to a series of clinical trials conducted for nearly 15 years on the Thai-Myanmar border, recurrence of *P. vivax* infection after 63 days was higher by 3.6 to 4.2-fold among participants treated with artemether-lumefantrine and artesunate-atovaquone-proguanil combinations compared to those treated with artemisinin-based combinations involving mefloquine or piperaquine [63].

ACTs containing mefloquine or piperaquine are better than ACTs containing AL at delaying the risk of recurrence. However, time-dependent efficacy decline has been revealed by a systematic review that reported a 15% prevalence of *P. vivax* recurrence among ACT recipients after day 63. The risk of *P. vivax* recurrence raises with the number of days after any antimalarial treatment given for *P. falciparum* infection [12]. Also, artesunate monotherapy may lead to recrudescence of parasitemia in 40–50% of cases within 28 days owing to drug-induced dormancy [92]. A comparable result has been observed in France, on a patient who returned from Chad [91].

Slowly eliminated antimalarials reduce the likelihood of early recurrence. Douglas *et al.* reported that the cumulative risk of *P. vivax* recurrence secondary to *P. falciparum* mono-infection was 51.1% after treatment with rapidly eliminated drugs (t1/2 < 1 day), 35.3% after treatment with intermediate half-life drugs (t1/2 1–7 days), and 19.6% after treatment with slowly eliminated drugs (t1/2 > 7 days) (P < 0.001) by day 63 [63]. Consistently, the risk of recurrence was higher for AL than for DHA-PPQ

therapy. The proposed reason is the shorter dormancy of parasitemia for rapidly eliminated drugs, such as lumefantrine, in AL [12, 93].

Incorporating PQ, hypnozoiticidal drug, in standard malaria drugs reduces the risk of recurrence, particularly relapse. Primaquine, when combined with ACT and PQ, can reduce the risk of recurrence in *P. vivax* and *P. falciparum* co-endemic settings [12]. Consistent with this, PQ combined with either CQ or AL has reduced the recurrence of *P. vivax* infection among G-6-PD wild patients by 5-fold for 1 year in Ethiopia [76]. Considering a one-year-long RCT in Thailand, a high dose of PQ (7 mg/kg) over 7 or 14 days is efficacious in preventing *P. vivax* relapse. Similarly, at least one episode of *P. vivax* recurrence has occurred among 70% of subjects in non-PQ arms compared to 18% of subjects in the PQ arm [15].

According to a systematic review by Commons *et al.*, the risk of *P. vivax* recurrence with a lower dose of CQ was 32.4% (95% CI: 29.8–35.1) by day 42. However, raising the dose substantially reduced the risk. Furthermore, including PQ in the treatment significantly reduced the risk of recurrence by day 42 from (AHR = 0.82 95% CI: 0.69–0.97; P = 0.021) with CQ alone to (AHR = 0.10, 0.05–0.17; P < 0.0001) with CQ and PQ. This strengthens the concept of the role of PQ as a radical cure in effectively preventing the early recurrence of *P. vivax* [89]. Nevertheless, despite the renowned efficacy of PQ, few pieces of evidence are emerging on malaria recurrence after radical therapy. Considering the tests, they used microscopy and the unknown status of CYP2D6, these pieces of evidence reflect treatment failure, but do not confirm drug resistance [79]. After its introduction, ACT rendered the rate of recrudescence to be below 10% in Jimma zone, southwest Ethiopia [77]. It is strongly considered that the probability of artemisinin resistance with a standard dose, a 3 day ACT, is rare if the proportion of day 3 positive smears is below 3% [94].

### *4.2.3.2 Place*

In co-endemic locations, patients presenting with *P. falciparum* are highly likely to carry *P. vivax* hypnozoites that give rise to recurrence [12, 80]. Patients in regions of short relapse periodicity had a greater rate of *P. vivax* parasitemia than those in regions of long periodicity (HR = 8.61 95% CI: 2.34–31.65; P = 0.001) [12]. Also, the risk of *P. vivax* parasitemia was 6.5% (95% CI: 4.6–8.6) in regions of short periodicity compared with 1.9% (95% CI: 0.4–4.0) in areas of long periodicity [12, 17]. Therefore, geographical variation determines the frequency of malaria recurrence.

### *4.2.3.3 Season*

A dormant hypnozoite of *P. vivax* awaits the right time for activation to take evolutionary advantage, thereby ensuring maximum likelihood of transmission and immune evasion. To ensure optimum transmission, hypnozoites synchronize their wake-up time to a season with an abundant mosquito population [20]. Thus, the incidence of symptomatic malaria was higher in September (OR = 2.81 95% CI: 2.1–3.7) and October (OR = 2.4 95% CI: 1.8–3.2) than in November [95].

### **5. Recurrence and malaria transmission**

Malaria recurrence, in addition to rising clinical episodes, increases the probability of malaria transmission. In fact, all types of malaria recurrence increase transmission

### *Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

in multidimensional ways, including by raising longevity of infectiousness and transmission potential [6, 11, 20]. A systematic review and meta-analysis result revealed that recrudescent (AOR = 9.05 95% CI: 3.74–21.9) and reinfection (AOR = 3.03 95% CI: 1.66–5.54) with *P. falciparum* were strongly associated with gametocytemia after day 7 [29]. Hence, recurrent infections with *Plasmodium* species maintain the potential for malaria transmission [6, 9, 16].

Recurring malaria leads to erythrocytic schizogony that renews or escalates peripheral parasitemia. Such parasitemia entails gametocytogenesis that maintains the transmission of malaria, thereby complicating elimination and eradication efforts [6, 16, 96, 97]. Moreover, activation of hypnozoites from different earlier inoculations can produce at least two genotypes simultaneously growing inside the patient's blood. This produces genetically distinct gametocytes that, if taken by a mosquito, have a high probability to undergo meiotic recombination resulting in genetic variation. This phenomenon is considered as a major factor for high degree

### **Figure 7.**

*Pattern of malaria recurrence, spots to intervene, and its prevention strategies. Parasitemia in peripheral circulation can be due to symptomatic, asymptomatic, or sub-microscopic plasmodium infection. This peripheral parasitemia can also arise from any type of malaria recurrence. (red boxes): After arriving in the liver, the inoculated sporozoites either transform into schizonts or directly become hypnozoites that later can become schizonts. Schizonts arising from latent hypnozoites or the inoculated sporozoites release merozoites that join the blood circulation to eventually produce asexual parasites. (purple boxes and lines): Young gametocytes localize into the hematopoietic niche and rejoin the circulation when reach stage five gametocyte. Gametocytes can result from unsuccessful treatment, after successful treatment with non-gametocidal drugs, and any untreated infection. These gametocytes mediate the transmission of malaria. (broken blue lines): Asexual parasites that periodically sequester in the hematopoietic niche and return into circulation resulting in relapse-like parasitemia. (blue solid lines): Flow of malaria pathogenesis from primary and reinfection subsequent to inoculation of sporozoites. (black line): Parasites sequestering in the hematopoietic niche. (greenish-yellow box and lines): Unsuccessful treatment and sub-microscopic infections give rise to recrudescence and/or possible transmission. (Green lines): Possible weak points for intervention (such as prompt diagnosis and effective treatment with efficacious radical cure, and transmission-blocker) to tackle recurrence and/or transmission.*

of genetic diversity seen in *P. vivax* over settings with very low seasonal transmission [17]. Hence, recurrence confers *P. vivax* with maximum opportunity for transmission and immune evasion [20].

Recurrence of *P. vivax* worsens transmission of malaria with its potential to promptly produce gametocytes and transmit before treatment initiation. In addition, due to the continued reactivation of hypnozoite, the patient remains a potential reservoir of infection for a long time from just a single inoculum [9, 97]. The probability of relapse and subsequent transmission raises with a load of hypnozoite in the liver [6, 60]. Furthermore, if the recurrence involves a heterologous genotype, it paves the ways for the development of drug resistance, thereby transmission of variant species. The variant species together with other factors cause recrudescence, which expands the pool of recurrence, and the subsequent transmission [20]. Besides, reinfection further exacerbates transmission dynamics with its potential to activate hypnozoite; introduce a new strain unresponsive to therapy and provides an opportunity for immune evasion [11].

Generally, malaria recurrence sustains and/or intensifies transmission. It raises efficiency, chance, and longevity of transmission, thus threatening the success of interventions [11]. Thus, it is wise to consider fighting recurrence to break transmission and eliminate malaria (**Figure 7**) [60, 96–98].

### **6. Recurrence and malaria elimination strategies**

The axiom "prevention is better than cure" better describes the impact of recurrence on the efforts to eliminate malaria [9, 85]. The difficulty to diagnose and treat malaria substantially increases morbidity and mortality among patients. Relapse due to vivax malaria is refractory to the majority of the current treatments since the sole hypnozoiticidal-drug, PQ, is challenged by many factors [9, 20]. The use of ACT will more noticeably reduce the prevalence of *P. falciparum* prevalence than *P. vivax* due to its inability to kill the hypnozoite forms of *P. vivax* [19].

A relapse followed by asymptomatic parasitemia could be the major approach to *P. vivax* transmission [20]. Particularly recurrence from asymptomatic infections is the major challenge to the elimination of malaria as they arrive at the gametocyte stage at the level below the sensitivity of the current gold standard tool for malaria diagnosis: light microscopy [9, 17]. Asymptomatic *P. vivax* infections are common in malariaendemic locations [36]. However, the contribution of relapse for asymptomatic malaria is not well known [9, 16, 19].

Vivax malaria remained the major global challenge despite a spectacular achievement against *P. falciparum* [74]. The complex nature of *P. vivax*, mainly due to relapse, extensively wrinkled the effectiveness of the radical cure with PQ. A considerable portion of the global population has difficulty converting PQ into its active form, hence the increased risk of recurrence [9]. Pregnant women and children below 6 months old owing to their ineligibility to PQ are at risk of vivax malaria and its recurrence. They can also serve as potential human reservoirs of infection [9, 85]. Hence, it is prevention that helps to keep this ever-complicating parasite at its bay [9, 16, 17, 99].

The possibility of relapse secondary to treatment and/or immunologic response to *P. falciparum* infection perpetuates the transmission in co-endemic settings. The growing phenomena of resistance to antimalarials, such as CQ and ACT, is another fuel to recurrence. The ineligibility of the vast majority of population to PQ given their physiological and genetic condition places a hurdle on the stride toward preventing recurrence [9].

*Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

The frequent possibility of mutation in *P. vivax* owing to cross-reactivity between strain arising from hypnozoite and strain from mosquito in an environment challenges the efficacy of therapies [14, 17]. Different intervals of recurrence resulting from the variation of *P. vivax* population in tropics (frequent relapse) and temperate (long latency) regions is another nightmare. Moreover, the capacity to remain sub-clinical and submicroscopic with huge potential to quickly produce gametocytes offers the cutting-edge to this parasite triumph [11, 17, 20, 100].

In general, the recurrence of *Plasmodium* infection, especially the *P. vivax* relapse, is the major setback to malaria elimination strategies of the time. Consequently, there is a renewed focus on *P. vivax* due to the mounting accumulation of evidence on the maliciousness of vivax malaria [9]. To achieve malaria eradication goal, we must consider all species of *Plasmodium*; while improving the transmission-reducing potential of interventions [6, 14, 19]. It is key to underpin prevention mainly for infants and pregnant women, while keeping the search for targets of intervention to stay in the game [9].

### **7. Conclusion and future remarks**

Malaria recurrence plays a considerable part in sustaining malaria epidemiology. Understanding the biology and epidemiology of malaria recurrence is crucial to overcome current challenges to efforts in malaria elimination. Malaria recurrence is not adequately studied partly due to the complex nature of the disease and logistic constraints for diagnosis. Regardless of its role in complicating clinical and public health impact of malaria, a basic understanding of malaria recurrence is limited. In this review, we have discussed the biology and epidemiology of malaria recurrence along with its implication on malaria mitigation.

Recurring malaria leads to increased morbidity and mortality due to malaria. By creating opportunities for gametocytogenesis, it sustains malaria transmission. Without identifying the specific *Plasmodium* species responsible for recurrence in specific areas limits the effectiveness of interventions. Lack of clear idea about the specific type of recurrence raises misconception on drug efficacy that eventually leads to hasty prohibition of antimalarials without robust replacement. Without effective intervention based on a clear understanding of recurrent malaria, morbidity and mortality continue to escalate due to recurrence. Unmanaged recurrent malaria maintains transmission of malaria. Hence, failure to promptly deal with recurrent malaria in a certain area has a huge impact on the health of individuals and the community at large.

Due to its widespread prevalence, relapse propensity, complex process of diagnosis and treatment, as well as other aspects, *P. vivax* demands continued multidimensional research. Studies should focus on the biology of malaria recurrence to improve the yield of control interventions. Optimizing disease-control interventions prevent a recurrence and breaks transmission to eliminate malaria.

### **8. Outstanding questions**


### **9. Search strategy and selection criteria**

We searched PubMed, the Cochrane Library, Science Direct, and Google Scholar for articles published in English between January 01, 2000, and December 31, 2021, with the terms "malaria recurrence," "malaria relapse," "malaria reinfection," "*Plasmodium* vivax," "recurrent parasitemia," "malaria recrudescence" and combined with the terms "glucose-six-phosphate dehydrogenase, "primaquine." We also included review studies (published between January 01, 2000, and December 31, 2021) cited by articles identified by this search strategy and selected those we identified as relevant. Selected review articles are cited to provide readers with more details and references than this review can accommodate.

### **Acknowledgements**

The author is grateful to Mr. Wasihun Admassu for his important comments on the first draft of this paper. The author also thanks Mr. Ahmed Kamil for his help in the drawing process of diagrams.

*Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

### **Author's contributions**

AA has conceived and designed this review. AA has participated in the acquisition of data and preparation of the draft manuscript. AA is involved in drafting, critically reviewing, and final approval of this manuscript.

### **Abbreviations**


## **Author details**

Aklilu Alemayehu1,2

1 School of Medical Laboratory Sciences, Institute of Health, Jimma University, Jimma, Ethiopia

2 Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Arba Minch University, Arba Minch, Ethiopia

\*Address all correspondence to: aaakealex59@gmail.com

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## **References**

[1] World Health Organization. Global Malaria Programme. WHO Malaria Terminology. Geneva: WHO; 2019

[2] Encyclopedia of Malaria. New York: Springer Science+Business Media; 2013

[3] Marcus MB. The hypnozoite concept, with particular reference to malaria. Parasitology Research. 2011;**108**:247-252

[4] *P. vivax* Information Hub. Knowledge sharing for Relapsing Malaria. Focus on: Relapse, Reinfection or Recrudescence. 2021. Available from: www.vivaxmalaria. org

[5] World Health Organization. Medicines for Malaria Venture. Methods and techniques for clinical trials on antimalarial drug efficacy: Genotyping to identify parasite populations. In: Informal Consultation Organized by the Medicines for Malaria Venture and Cosponsored by the World Health Organization. Amesterdam: WHO; 2008

[6] Markus MB. Biological concepts in recurrent *P. vivax* malaria. Parasitology. 2018;**143**(13):1-7

[7] World Health Organization Global Malaria Programme. Report on Antimalarial Drug Efficacy, Resistance and Response: 10 Years of Surveillance (2010-2019). Geneva: WHO; 2020

[8] World Health Organization. WHO Guidelines for Malaria. Geneva: WHO; 2021

[9] Baird JK. Malaria caused by *P. vivax*: Recurrent, difficult to treat, disabling, and threatening to life- averting the infectious bite preempts these hazards. Pathogens and Global Health. 2013;**107**(8):475-479

[10] Lau YL, Tan LH, Chin LC, Fong MY, Noraishah MA, Rohela M. *P. knowlesi* reinfection in human. Emerging Infectious Diseases. 2011;**17**(7):1314

[11] Águas R, Ferreira MU, Gomes MGM. Modeling the effects of relapse in the transmission dynamics of malaria parasites. Journal of Parasitology Research. 2012;**2012**:1-15

[12] Commons RJ, Ja S, Thriemer K, Hossain MS, Douglas NM, Humphreys GS, et al. Risk of *P. vivax* parasitemia after *P. falciparum* infection: A systematic review and meta-analysis. The Lancet Infectious Diseases. 2019;**19**(1):91-101

[13] White NJ. How antimalarial drug resistance affects post-treatment prophylaxis. Malaria Journal. 2008;**7**(9):1-7

[14] McCann RS, Cohee LM, Goupeyou-Youmsi J, Laufer MK. Maximizing impact: Can interventions to prevent clinical malaria reduce parasite transmission? Trends in Parasitology. 2020;**36**(11):906-913

[15] Chu C. Management of relapsing *P. vivax* malaria. International Journal of Infectious Diseases. 2016;**45**:16

[16] Markus MB. Malaria eradication and the hidden parasite reservoir. Trends in Parasitology. 2017;**33**(7):492-495

[17] White NJ. Determinants of relapse periodicity in *P. vivax* malaria. Malaria Journal. 2011;**10**(297):1-36

[18] Brasil P, Costa ADP, Pedro RS, Bressan CS, Silva S, Tauil PL, et al. Unexpectedly long incubation period of *P. vivax* malaria, in the absence of chemoprophylaxis, in patients diagnosed *Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

outside the transmission area in Brazil. Malaria Journal. 2011;**10**(122):1-5

[19] World Health Organization. Confronting *P. vivax* Malaria. Geneva: WHO; 2015

[20] White NJ. Why do some primate malarias relapse? Trends in Parasitology. 2016;**32**(12):918-920

[21] Obaldia N III, Meibalan E, Sa JM, Ma S, Clark MA, Mejia P, et al. Bone marrow is a major parasite reservoir in *P. vivax* infection. MBio. 2018;**9**(3):e00625-e00618

[22] Markus MB. New evidence for Hypnozoite-Independent *P. vivax* malarial recurrences. Trends in Parasitology. 2018;**34**(12):1015-1016

[23] Silva-Filho JL, Lacerda MVG, Recker M, Wassmer SC, Marti M, Costa FTM. *P. vivax* in hematopoietic niches: Hidden and dangerous. Trends in Parasitology. 2020;**36**(5):447-458

[24] Bright AT, Tewhey R, Arango EM, Wang T, Schork NJ, et al. A highresolution case study of a patient with recurrent *P. vivax* infections shows that relapses were caused by meiotic siblings. PLOS Neglected Tropical Disease. 2014;**8**(6):e2882

[25] Battle KEKM, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in *P. vivax* relapse. Malaria Journal. 2014;**13**(144):1-16

[26] Chamchod F, Beier JC. Modeling *P. vivax*: Relapses, treatment, seasonality, and G6PD deficiency. Journal of Theoretical Biology. 2013;**316**:25-34

[27] Mueller I, Galinski MR, P JKB, Carlton JM, Kochar DK, Alonso PL, et al. Key gaps in knowledge of *P. vivax*, a neglected human malaria parasite.

The Lancet Infectious Diseases. 2009;**9**(9):555-566

[28] Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, et al. Reduced artemisinin susceptibility of *P. falciparum* ring stages in western Cambodia. Antimicrobial Agents and Chemotherapy. 2013;**57**:914-923

[29] Abdulla S, Achan J, Adam I, Alemayehu BH, Allan R, Allen EN, et al. Gametocyte carriage in uncomplicated *P. falciparum* malaria following treatment with artemisinin combination therapy: A systematic review and meta-analysis of individual patient data. BMC Medicine. 2016;**14**(1):1-18

[30] Cheng Z. Advances in molecular diagnosis of malaria. In: Makowski G, editor. Adv Clin Chem. 80: Academic Press; 2017

[31] World Health Organization. Global Technical Strategy for Malaria 2016- 2030. Geneva: WHO; 2015

[32] Tedla M. A focus on improving molecular diagnostic approaches to malaria control and elimination in low transmission settings: Review. Parasite Epidemiology and Control. 2019;**6**:e00107

[33] Snounou G, Singh B. Nested PCR analysis of *plasmodium* parasites. In: Doolan DL, Editor. Methods Mol Med. 72. Totowa: Humana Press; 2002

[34] Hemingway J, Shretta R, Wells TNC, Bell D, Djimdé A, Achee N, et al. Tools and strategies for malaria control and elimination: What do we need to achieve a grand convergence in malaria? PLoS Biology. 2016;**14**(3):e1002380

[35] Green MR, Sambrook J. Nested Polymerase Chain Reaction (PCR). Huntington: Cold Spring Harbor Laboratory Press; 2019

[36] Assefa A, Ahmed AA, Deressa W, Wilson GG, Kebede A, Mohammed H, et al. Assessment of subpatent *plasmodium* infection in northwestern Ethiopia. Malaria Journal. 2020;**19**(108):1-10

[37] World Health Organization. Testing for G6PD Deficiency for Safe Use of Primaquine in Radical Cure of *P. Vivax* and *P. ovale* Malaria: Policy Brief. Geneva: WHO; 2016

[38] Canier L, Khim N, Kim S, Sluydts V, Heng S, Dourng D, et al. An innovative tool for moving malaria PCR detection of parasite reservoir into the field. Malaria Journal. 2013;**12**(405):1-12

[39] Perandin F. Development of a real-time PCR assay for detection of *P. falciparum, P. vivax, and P. ova*le for routine clinical diagnosis. Journal of Clinical Microbiology. 2004;**42**(3):1214-1219

[40] Rubio J, Benito A, Roche J, Berzosa P, Garcia M, Mico M, et al. Semi-nested, multiplex polymerase chain reaction for detection of human malaria parasites and evidence of *P. vivax* infection in Equatorial Guinea. American Journal of Tropical Medicine and Hygiene. 1999;**60**:183-187

[41] Thermo Fisher Scientific. Real-Time PCR Handbook 2021 [cited 2021 22/12/2021]. Available from: https:// www.thermofisher.com/qpcr

[42] Kralik P, Ricchi M, Donu D. A basic guide to real time PCR in microbial diagnostics: Definitions, parameters, and everything. Frontiers in Microbiology. 2017;**8**(108):1-15

[43] Nsanzabana C, Djalle D, Guerin PJ, Menard D, Gonzalez IJ. Tools for surveillance of antimalarial-drug resistance: An assessment of current landascape. Malaria Journal. 2018;**17**(75):1-16

[44] Haanshuus CG, Mørch K, Blomberg B, Strøm GEA, Langeland N, Hanevik K, et al. Assessment of malaria real-time PCR methods and application with focus on lowlevel parasitaemia. PLoS One. 2019;**14**(7):1-15

[45] Leski TA, Taitt CR, Swaray AG, Bangura U, Reynolds ND, Holtz A, et al. Use of real-time multiplex PCR, malaria rapid diagnostic test and microscopy to investigate the prevalence of *plasmodium* species among febrile hospital patients in Sierra Leone. Malaria Journal. 2020;**19**(84):1-8

[46] Genomics F. What is Multiplex PCR? 2021. Available from: https:// frontlinegenomics.com/what-ismultiplex-pcr/.

[47] Malaria Methods and Protocols. Doolan DL, editor. Totowa, New Jersey: Humana Press; 2017

[48] Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. Genome sequence of the human malaria parasite *plasmodium* falciparum. Nature Biotechnology. 2002;**419**:398-411

[49] Siegel SV, Rayner JC. Single cell sequencing shines a light on malaria parasite elatedness in complex infections. Trends in Parasitology. 2020;**36**(2):83-85

[50] Ford A, Kepple D, Abagero BR, Connors J, Pearson R, Auburn S, et al. Whole genome sequencing of *P. vivax* isolates reveals frequent sequence and structural polymorphisms in erythrocyte binding genes. PLoS Neglected Tropical Diseases. 2020;**14**(10):1-27

[51] Menard D, Chan ER, Benedet C, Ratsimbasoa A, Kim S, Chim P, et al. Whole genome sequencing of field isolates reveals a common duplication of the Duffy binding protein gene in

*Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

Malagasy *plasmodium* vivax strains. PLoS Neglected Tropical Diseases. 2013;**7**(11):1-15

[52] The malERA refresh consultative panel on Characterising the reservoir and measuring transmission malERA. An updated research agenda for characterising the reservoir and measuring transmission in malaria elimination and eradication. PLoS Medicine. 2017;**14**(11):e1002452

[53] Boussaroque A, Fall B, Madamet M, Camara C, Benoit N, Mansour FG, et al. Emergence of mutations in the K13 propeller gene of *P. falciparum* isolates from Dakar, Senegal, in 2013-2014. Antimicrobial Agents and Chemotherapy. 2016;**60**(1):624-627

[54] Heuchert A, Abduselam N, Zeynudin A, Eshetu T, Löscher T, Wieser A, et al. Molecular markers of anti-malarial drug resistance in Southwest Ethiopia over time: Regional surveillance from 2006 to 2013. Malaria Journal. 2015;**14**(1):1-7

[55] Tessema SK, Raman J, Duffy CW, Ishengoma DS, Amambua-Ngwa A, Greenhouse B. Applying next-generation sequencing to track falciparum malaria in sub-Saharan Africa. Malaria Journal. 2019;**18**(1):1-9

[56] Anjum MU, Naveed AK, Mahmood SN, Naveed OK. Single dose tafenoquine for preventing relapse in people with *P. vivax* malaria-an updated meta-analysis. Travel Medicine and Infectious Diseases. 2020;**36**(October 2019):101576

[57] Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. *P. Vivax* in the era of the shrinking *P. falciparum* map. Trends in Parasitology. 2020;**36**(6):560-570

[58] Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Suen CSLW. Strategies for understanding and reducing the *P. vivax* and *P. ovale* hypnozoite reservoir in Papua new Guinean children: A randomized placebo controlled trial and mathematical model. PLOS Medicine. 2015;**12**:e1001891

[59] Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: A retrospective cohort study. BMC Medicine. 2020;**18**(28):1-12

[60] White MT, Karl S, Battle KE, Hay SI, Mueller I, Ghani AC. Modelling the contribution of the hypnozoite reservoir to *P. vivax* transmission. eLife. 2014;**3**:e04692

[61] World Health Organization. Control and Elimination of *P. Vivax* Malaria- a Technical Brief. Geneva: WHO; 2015

[62] Lawpoolsri S, Sattabongkot J, Sirichaisinthop J, Cui L, Kiattibutr K, Rachaphaew N, et al. Epidemiological profiles of recurrent malaria episodes in an endemic area along the Thailand-Myanmar border: A prospective cohort study. Malaria Journal. 2019;**18**(1):1-11

[63] Douglas NM, Nosten F, Ea A, Phaiphun L, Van Vugt M, Singhasivanon P, et al. *P. vivax* recurrence following falciparum and mixed species malaria: Risk factors and effect of antimalarial kinetics. Clinical Infectious Diseases. 2011;**52**(5):612-620

[64] Worldwide Antimalarial Resistance Network. A high risk of *P. vivax* after *P. falciparum* infection. 2019

[65] Ma S, Wajihullah SMI, Al-Khalifa MS. Malaria: Patterns of relapse and resistance. Journal of King Saud University- Science. 2010;**22**(1):31-36

[66] Simões LR, Alves ER, Ribatski-Silva D, Gomes LT, Nery AF, Fontes CJF. Factors associated with recurrent *P. vivax* malaria in Porto Velho, Rondônia state, Brazil, 2009. Cadernos de Saúde Pública. 2014;**30**(7):1403-1417

[67] Popovici J, Pierce-Friedrich L, Kim S, Bin S, Run V, Lek D, et al. Recrudescence, reinfection, or relapse? A more rigorous framework to assess chloroquine efficacy for *P. vivax* malaria. Journal of Infectious Diseases. 2019;**219**(2):315-322

[68] Zuluaga-Idárraga L, Blair S, Okoth SA, Udhayakumar V, Marcet PL, Aa E, et al. Prospective study of *P. vivax* malaria recurrence after radical treatment with a chloroquineprimaquine standard regimen in turbo, Colombia. Antimicrobial Agents and Chemotherapy. 2016;**60**(8):4610-4619

[69] Ismail A, Auclair F, McCarthy AE. Recrudescence of chronic *P. falciparum* malaria 13 years after exposure. Travel Medicine and Infectious Diseases. 2020;**October 2019**(33):101518

[70] Hviid L. Naturally acquired immunity to *P. falciparum* malaria in Africa. Acta Tropica. 2005;**95**:270-275

[71] Oboh MA, Oyebola KM, Idowu ET, Badiane AS, Otubanjo OA, Ndiaye D. Rising report of *P. vivax* in sub-Saharan Africa: Implications for malaria elimination agenda. Scientific African. 2020;**10**:e00596-e

[72] Fulakeza JRM, Banda RL, Lipenga TR, Terlouw DJ, Nkhoma SC, Hodel EM. Comparison of two genotyping methods for distinguishing recrudescence from reinfection in antimalarial drug efficacy trials. American Journal of Tropical Medicine and Hygiene. 2018;**99**(1):84-86

[73] Collins WE, Jeffery GM, Roberts JM. Aretrospective examination of reinfection of humans with *P. vivax*. American Journal of Tropical Medicine and Hygiene. 2004;**70**(6):642-644

[74] World Health Organization. World Malaria Report 2020: 20 Years of Global Progress and Challenges. Geneva: WHO; 2021

[75] Hwang J, Alemayehu BH, Hoos D, Melaku Z, Tekleyohannes SG, Teshi T, et al. In vivo efficacy of artemetherlumefantrine against uncomplicated *P. falciparum* malaria in Central Ethiopia. Malaria Journal. 2011;**10**:1-10

[76] Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of *P. vivax* infection in Ethiopia: A randomized controlled trial. PLoS Medicine. 2017;**14**(5):e1002299-e

[77] Eshetu T, Abdo N, Bedru KH, Fekadu S, Wieser A, Pritsch M, et al. Open-label trial with artemetherlumefantrine against uncomplicated *P. falciparum* malaria three years after its broad introduction in Jimma zone, Ethiopia. Malaria Journal. 2012;**11**:1-11

[78] Yohannes A, Teklehaimanot A, Bergqvist Y, Ringwald P. Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. American Journal Tropical Medicine and Hygiene. 2011;**84**:137-140

[79] Teklehaimanot A, Teklehaimanot H, Girmay A, Woyessa A. Case report: Primaquine failure for radical cure of *P. vivax* malaria in Gambella, Ethiopia. American Journal of Tropical Medicine and Hygiene. 2020;**103**(1):415-420

*Biology and Epidemiology of Malaria Recurrence: Implication for Control and Elimination DOI: http://dx.doi.org/10.5772/intechopen.108888*

[80] Hossain MS, Commons RJ, Douglas NM, Thriemer K, Alemayehu BH, Amaratunga C, et al. The risk of *P. vivax* parasitemia after *P. falciparum* malaria: An individual patient data meta-analysis from the WorldWide antimalarial resistance network. PLoS Medicine. 2020;**17**(11):1-26

[81] Ariffin N, Islahudin F, Kumolosasi E, Makmor-Bakry M. Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers. Parasitology Research. 2019;**118**:1011-1018

[82] Baird JK, Louisa M, Noviyanti R, Ekawati L, Elyazar I, Subekti D, et al. Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of Primaquine treatment for Latent *P. vivax* malaria. JAMA Network Open. 2018;**1**(4):1-12

[83] Zhou Y, Ingelman-Sundberg M, Lauschke V. Worldwide distribution of cytochrome P450 alleles: A meta-analysis of population-scale sequencing projects. Clinical Pharmacology and Therapy. 2017;**102**(4):688-700

[84] von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: A workshop report. Malaria Journal. 2013;**12**(112):1-12

[85] Watson J, Taylor WRJ, Bancone G, Chu CS, Jittamala P, White NJ. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. PLoS Neglected Tropical Diseases. 2018;**12**(4):1-14

[86] Corder RM, de Lima ACP, Khoury DS, Docken SS, Davenport MP, Ferreira MU. Quantifying and preventing *P. vivax* recurrences in primaquineuntreated pregnant women: An observational and modeling study in Brazil. PLoS Neglected Tropical Diseases. 2020;**14**(7):1-16

[87] Daher A, JCaL S, Stevens A, Marchesini P, Fontes CJ, Ter Kuile FO, et al. Evaluation of *P. vivax* malaria recurrence in Brazil. Malaria Journal. 2019;**18**(18):1-10

[88] Siqueira AM, Alencar AC, Melo GC, Magalhaes BL, Machado K, Alencar Filho AC, et al. Fixed-dose Artesunate-Amodiaquine combination vs chloroquine for treatment of uncomplicated blood Stage *P. vivax* infection in the Brazilian Amazon: An open-label randomized controlled trial. Clinical Infectious Disease. 2017;**64**:166-174

[89] Commons RJ, Ja S, Thriemer K, Humphreys GS, Abreha T, Alemu SG, et al. The effect of chloroquine dose and primaquine on *P. vivax* recurrence: A WorldWide antimalarial resistance network systematic review and individual patient pooled meta-analysis. The Lancet Infectious Diseases. 2018;**18**(9):1025-1034

[90] von Seidlein L, Peerawaranun P, Mukaka M, Nosten F, Nguyen T, Hien T, et al. The probability of a sequential *P. vivax* infection following asymptomatic *P. falciparum* and *P. vivax* infections in Myanmar, Vietnam, Cambodia, and Laos. Malaria Journal. 2019;**18**(449):1-7

[91] Landre S, Bienvenu AL, Miailhes P, Abraham P, Simon M, Becker A, et al. Recrudescence of a high parasitaemia, severe *P. falciparum* malaria episode, treated by artesunate monotherapy.

International Journal of Infectious Diseases. 2021;**105**:345-348

[92] Wellems T, Sá J, Su X-Z, Connelly S, Ellis A. "Artemisinin resistance": Something new or old? Something of a misnomer? Trends in Parasitology. 2020;**36**:735-744

[93] Arinaitwe E. Artemetherlumefantrine versus dihydroartemisininpiperaquine for falciparum malaria: A longitudinal, randomized trial in young Ugandan children. Clinical Infectious Disease. 2009;**49**:1629-1637

[94] Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, et al. In vivo parasitological measures of artemisinin susceptibility. Journal of Infectious Disease. 2010;**201**:570-579

[95] Degefa T, Zeynudin A, Zemene E, Emana D, Yewhalaw D. High prevalence of gametocyte carriage among individuals with asymptomatic malaria: Implications for sustaining malaria control and elimination efforts in Ethiopia. Human Parasitic Diseases. 2016;**8**:17-25

[96] The malERA refresh consultative panel on characterizing the reservoir and measuring transmission malERA. An updated research agenda for characterizing the reservoir and measuring transmission in malaria elimination and eradication. PLoS Medicine. 2017;**14**(11):e1002452

[97] The malERA refresh consultative panel on basic science and enabling technologies malERA. An updated research agenda for basic science and enabling technologies in malaria elimination and eradication. PLoS Medicine. 2017;**14**(11):e1002451

[98] World Health Organization. A Framework for Malaria Elimination. Geneva: WHO; 2017

[99] Rishikesh K, Saravu K. Primaquine treatment and relapse in *P. vivax* malaria. Pathogens and Global Health. 2016;**110**(1):1-8

[100] White MT, Walker P, Karl S, Hetzel MW, Freeman T, Waltmann A, et al. Mathematical modelling of the impact of expanding levels of malaria control interventions on *P. vivax*. Nature Communications. 2018;**9**(3300):1-10

Section 4
